Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (201-210 of 410) with videos related to

Pageof 41
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|April 22, 2026
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyDingwei Ye, Marniza Saad, Ji Youl Lee, et al.
European Urology|December 18, 2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE StudyNobuaki Matsubara, Kim N Chi, Mustafa Özgüroğlu, et al.
Lab on a Chip|May 16, 2018
Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissectionEmily S Park, Justin P Yan, Richard A Ang, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
Journal of Cancer Research and Clinical Oncology|October 12, 2022
Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancerWendy W Y Choi, Catherine Sánchez, Jiao Jiao Li, et al.
The Oncologist|March 30, 2023
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study ResultsKim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
The Lancet. Oncology|April 17, 2019
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trialKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
Pageof 41

Showing results (201-210 of 410) with videos related to

Sort By:
Pageof 41
International Journal of Urology : Official Journal of the Japanese Urological Association|April 22, 2026
Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE StudyDingwei Ye, Marniza Saad, Ji Youl Lee, et al.
European Urology|December 18, 2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE StudyNobuaki Matsubara, Kim N Chi, Mustafa Özgüroğlu, et al.
Lab on a Chip|May 16, 2018
Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissectionEmily S Park, Justin P Yan, Richard A Ang, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
Journal of Cancer Research and Clinical Oncology|October 12, 2022
Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancerWendy W Y Choi, Catherine Sánchez, Jiao Jiao Li, et al.
The Oncologist|March 30, 2023
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study ResultsKim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
The Lancet. Oncology|April 17, 2019
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trialKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
Pageof 41